Sign up
Pharma Capital

Cesca Therapeutics rises after subsidiary wins Health Canada OK of umbilical-cord blood processing

The FDA has already cleared the AXP system, which is used worldwide by public and private umbilical cord-blood banks for the collection of stem cells
stem cells
Cesca develops, commercializes, and markets a range of automated technologies for cell-based therapies

Shares of Cesca Therapeutics Inc (NASDAQ:KOOL) received a boost Tuesday after its subsidiary ThermoGenesis Corp received Health Canada approval of its next-generation AXP II system for cord-blood processing.

The AXP II provides automated harvesting of stem and progenitor cells from collected units of umbilical-cord blood in a sterile system. The US Food and Drug Administration has cleared the system, which is used worldwide by public and private cord-blood banks for the collection of stem cells.

Cesca Therapeutics’ stock recently traded up 26% to $3.51 a share on higher-than-average volume.

READ: Shares of Jaguar Health jump on news federal government will help develop its cholera drug lechlemer

"Health Canada's approval of the AXP II marks the achievement of yet another key milestone and should allow us to meaningfully expand our footprint with a best-in-class system that continues to hold a market-leading position,’’ said ThermoGenesis President Haihong Zhu. “That said, we look forward to building on our customer base by offering Cord Blood Banks throughout Canada.”

Based in Rancho Cordova, California, Cesca develops, commercializes, and markets a range of automated technologies for cell-based therapies in the US, China, Asia and Europe.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

1556543955_patrick.graham.jpg


Register here to be notified of future KOOL Company articles
View full KOOL profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.